Bradley M. Buchheit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bradley M. Buchheit has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Amy Kwon
Amy Kwon, MD, is Assistant Professor of Medicine, Division of General Internal Medicine and Geriatrics, Oregon Health & Science University, Portland, Oregon, USA; and
1 shared publication- Damian J. Krysan
Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA
1 shared publication - Eleasa Sokolski
Eleasa Sokolski, MD, is Assistant Professor of Medicine and Psychiatry, Division of General Internal Medicine & Geriatrics, Department of Medicine, Section of Addiction Medicine, Oregon Health & Science University, Portland, Oregon, USA
1 shared publication Elizabeth Salisbury-Afshar
Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA
1 shared publicationGrace Chen
Grace Chen, MD, is Assistant Professor of Anesthesiology and Perioperative Medicine and Program Director, Pain Medicine Fellowship, Oregon Health & Science University, Portland, Oregon, USA
1 shared publicationHolly Hagle
American Academy of Addiction Psychiatry, East Providence, RI, USA
1 shared publication
Latest Publications
- 4 March 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 617-627
Building Stronger Communities Through Addiction Care Innovation, Research, Education, and Advocacy—Overview and Proceedings of the AMERSA 2025 Conference
This commentary provides an overview of the 49th annual AMERSA conference, held from November 13 to 15, 2025, in Portland, OR. The conference featured 16 interactive workshops, over 160 oral abstract presentations, and 120 poster presentations. In alignment with the theme of Building Stronger Communities through Addiction Care Innovation, Research, Education and Advocacy, the conference program planning committee was committed to incorporating sessions, including plenaries, workshops, and abstract presentations, which focused on expanding access to resources and including community voices. Plenary topics included building rural peer networks to expand the reach of substance use and substance use disorder care, supportive housing, expanding access to medications for opioid use disorder in rural areas, and the use of psychedelics as an emerging treatment modality, among others. Workshops addressed topics such as building partnerships between academic and tribal communities, Community Reinforcement and Family Training for practitioners, addressing stigma associated with substance use, and strategies to access difficult-to-reach populations to provide care. Through session attendance and dialogue with peers from across geographies and disciplines, the conference created space for conversations that cut across silos and helped to shape evidence-informed, community-engaged practice.
- 4 March 2026
- Published by SAGE Publications in Substance use & addiction journal
- Vol. 47 (3) , 617-627
Building Stronger Communities Through Addiction Care Innovation, Research, Education, and Advocacy—Overview and Proceedings of the AMERSA 2025 Conference
This commentary provides an overview of the 49th annual AMERSA conference, held from November 13 to 15, 2025, in Portland, OR. The conference featured 16 interactive workshops, over 160 oral abstract presentations, and 120 poster presentations. In alignment with the theme of Building Stronger Communities through Addiction Care Innovation, Research, Education and Advocacy, the conference program planning committee was committed to incorporating sessions, including plenaries, workshops, and abstract presentations, which focused on expanding access to resources and including community voices. Plenary topics included building rural peer networks to expand the reach of substance use and substance use disorder care, supportive housing, expanding access to medications for opioid use disorder in rural areas, and the use of psychedelics as an emerging treatment modality, among others. Workshops addressed topics such as building partnerships between academic and tribal communities, Community Reinforcement and Family Training for practitioners, addressing stigma associated with substance use, and strategies to access difficult-to-reach populations to provide care. Through session attendance and dialogue with peers from across geographies and disciplines, the conference created space for conversations that cut across silos and helped to shape evidence-informed, community-engaged practice.
- Open Access
- 1 February 2024
- Published by Journal of Graduate Medical Education in Journal of Graduate Medical Education
- Vol. 16 (1) , 75-79
Five Key Articles on Curriculum Development for Graduate Medical Educators
Background Curriculum development is an essential domain for medical educators, yet specific training in this area is inconsistent. With competing demands for educators’ time, a succinct resource for best practice is needed. Objective To create a curated list of the most essential articles on curriculum development to guide education scholars in graduate medical education. Methods We used a modified Delphi method, a systematic consensus strategy to increase content validity, to achieve consensus on the most essential curriculum development articles. We convened a panel of 8 experts from the United States in curricular development, with diverse career stages, institutions, gender, and specialty. We conducted a literature search across PubMed and Google Scholar with keywords, such as “curriculum development” and “curricular design,” to identify relevant articles focusing on a general overview or approach to curriculum development. Articles were reviewed across 3 iterative Delphi rounds to narrow down those that should be included in a list of the most essential articles on curriculum development. Results Our literature search yielded 1708 articles, 90 of which were selected for full-text review, and 26 of which were identified as appropriate for the modified Delphi process. We had a 100% response rate for each Delphi round. The panelists narrowed the articles to a final list of 5 articles, with 4 focusing on the development of new curriculum and 1 on curriculum renewal. Conclusions We developed a curated list of 5 essential articles on curriculum development that is broadly applicable to graduate medical educators.
- 1 February 2024
- Published by Journal of Graduate Medical Education in Journal of Graduate Medical Education
- Vol. 16 (1) , 75-79
Open AccessFive Key Articles on Curriculum Development for Graduate Medical Educators
Background Curriculum development is an essential domain for medical educators, yet specific training in this area is inconsistent. With competing demands for educators’ time, a succinct resource for best practice is needed. Objective To create a curated list of the most essential articles on curriculum development to guide education scholars in graduate medical education. Methods We used a modified Delphi method, a systematic consensus strategy to increase content validity, to achieve consensus on the most essential curriculum development articles. We convened a panel of 8 experts from the United States in curricular development, with diverse career stages, institutions, gender, and specialty. We conducted a literature search across PubMed and Google Scholar with keywords, such as “curriculum development” and “curricular design,” to identify relevant articles focusing on a general overview or approach to curriculum development. Articles were reviewed across 3 iterative Delphi rounds to narrow down those that should be included in a list of the most essential articles on curriculum development. Results Our literature search yielded 1708 articles, 90 of which were selected for full-text review, and 26 of which were identified as appropriate for the modified Delphi process. We had a 100% response rate for each Delphi round. The panelists narrowed the articles to a final list of 5 articles, with 4 focusing on the development of new curriculum and 1 on curriculum renewal. Conclusions We developed a curated list of 5 essential articles on curriculum development that is broadly applicable to graduate medical educators.
- Open Access
- 1 December 2023
- Published by Journal of Graduate Medical Education in Journal of Graduate Medical Education
- Vol. 15 (6) , 632-637
It’s Time to Train Residents in Addiction Medicine
Over a decade has passed since O’Conner, Nyquist, and McLellan called for integrating addiction medicine into graduate medical education (GME).1 Since then, the need for substance use disorder (SUD) treatment in the United States has increased, with annual overdose deaths rising to 105 545 in 2022.2 In 2021, 46.3 million people aged 12 or older met DSM-5 criteria for SUD, but only 6% received treatment.3 Despite effective, life-saving therapies for opioid use disorder (OUD), 87% of patients do not receive evidence-based care.4 People with SUDs often experience stigma and harm when interacting with the health care system, leading to higher rates of patient-directed discharges from hospitals—an outcome associated with increased mortality.5,6 A prepared workforce is critical to meet this enormous treatment need.US graduating physicians remain largely ill-equipped to care for patients with SUD. A main driver is the lack of addiction medicine training during residency.7 Although many groups recommend increased residency SUD training,8 there is little information to show that GME experiences have improved. The current SUD treatment gap presents a pressing need for residency curriculum development, faculty education and leadership, institutional support for training sites, and efforts to reduce stigma.In response to the high prevalence of SUD, the Accreditation Council for Graduate Medical Education (ACGME) published a 2019 common program requirement that all programs provide education in pain management and recognition of addiction, if applicable to the specialty.9 Subsequently, the GME Stakeholders Congress on Preparing Residents and Fellows to Manage Pain and Substance Use Disorder created specialty-specific curriculum recommendations.10 The program requirements provide a start for curricular inspiration, but residents need a broader understanding of the neurobiology of addiction, recognition and management of a range of SUDs, and harm reduction. A robust curriculum should comprise interactive teaching conferences and clinical experiences that include working with addiction experts and interprofessional teams, including learning from peers and others with lived experience of addiction and its consequences.11,12 Each specialty will need to develop specific competencies relevant to the most common conditions and settings, with experiences and assessments to match these competencies (see Table for selected examples).Research on resident addiction medicine curricula has focused on single-site or single-specialty studies.13-15 However, a recent evaluation of the Family Medicine National Addiction Curriculum developed by the Society of Teachers in Family Medicine (STFM) found promising results, including changes in faculty and resident behaviors and practices across 25 family medicine residencies.16,17 Unique features of the STFM National Addiction Curriculum include a teacher’s guide for faculty members designed to support those with varying levels of addiction medicine expertise. Most specialty boards include only a few questions about SUD management in their certification examinations, which may provide less incentive for residency programs to include more content in the curriculum. For example, despite the high prevalence of SUD in the population18 less than 2% of the questions on the American Board of Internal Medicine certification exam concern SUDs.19 Adding SUD questions to in-training and specialty board certification examinations may further support robust development of curricular content.Another key barrier to residency SUD education is the lack of faculty expertise and faculty role models. Recognizing and providing treatment for SUDs should be a core competency for most physicians. With the US Medication Access and Training Expansion (MATE) act of 2023, the X-waiver has been replaced with a new 8-hour training requirement for the treatment of opioid and other SUDs for all Drug Enforcement Administration-registered physicians.20 While prescribing medication to treat SUDs is important, it is not sufficient. Residents should learn how to approach patients with a trauma-informed lens, motivate change, and engage patients in conversations of harm reduction. This requires faculty development and prioritization of SUD education by GME-sponsoring institutions.One option for faculty development is through continuing medical education (CME) programs such as the Provider Clinical Support System (PCSS) and the Extension for Community and Healthcare Outcomes (ECHO) programs.21 PCSS provides Buprenorphine Trainings (which have replaced the X-Waiver training) in addition to an extensive SUD 101 Curriculum. ECHO programs combine real-time virtual case discussions and didactic presentations. These programs may be used in combined faculty/resident sessions for shared learning, which can foster collegiality and mentoring opportunities. Practice-change leaders can ignite and support the pressing need for resident education and program development. National programs to support these leaders include the Boston University Clinical Addiction Research & Education Faculty Scholars Program and Chief Resident Immersion Training Program.22 The American College of Academic Addiction Medicine and American Society of Addiction Medicine provide additional CME opportunities and support for starting addiction medicine fellowships—a source for future program faculty. Many other resources are available (see online supplementary data).Currently, while many residents frequently care for patients with end-stage addiction, particularly in hospital and emergency department settings, they lack clinical experiences in optimal clinical settings.23 There is a national shortage of SUD clinical programs with experienced physician leaders.7,24,25 Thus, leaders at academic centers and teaching health systems should prioritize developing addiction medicine clinics and consult services both inpatient and...
- 1 December 2023
- Published by Journal of Graduate Medical Education in Journal of Graduate Medical Education
- Vol. 15 (6) , 632-637
Open AccessIt’s Time to Train Residents in Addiction Medicine
Over a decade has passed since O’Conner, Nyquist, and McLellan called for integrating addiction medicine into graduate medical education (GME).1 Since then, the need for substance use disorder (SUD) treatment in the United States has increased, with annual overdose deaths rising to 105 545 in 2022.2 In 2021, 46.3 million people aged 12 or older met DSM-5 criteria for SUD, but only 6% received treatment.3 Despite effective, life-saving therapies for opioid use disorder (OUD), 87% of patients do not receive evidence-based care.4 People with SUDs often experience stigma and harm when interacting with the health care system, leading to higher rates of patient-directed discharges from hospitals—an outcome associated with increased mortality.5,6 A prepared workforce is critical to meet this enormous treatment need.US graduating physicians remain largely ill-equipped to care for patients with SUD. A main driver is the lack of addiction medicine training during residency.7 Although many groups recommend increased residency SUD training,8 there is little information to show that GME experiences have improved. The current SUD treatment gap presents a pressing need for residency curriculum development, faculty education and leadership, institutional support for training sites, and efforts to reduce stigma.In response to the high prevalence of SUD, the Accreditation Council for Graduate Medical Education (ACGME) published a 2019 common program requirement that all programs provide education in pain management and recognition of addiction, if applicable to the specialty.9 Subsequently, the GME Stakeholders Congress on Preparing Residents and Fellows to Manage Pain and Substance Use Disorder created specialty-specific curriculum recommendations.10 The program requirements provide a start for curricular inspiration, but residents need a broader understanding of the neurobiology of addiction, recognition and management of a range of SUDs, and harm reduction. A robust curriculum should comprise interactive teaching conferences and clinical experiences that include working with addiction experts and interprofessional teams, including learning from peers and others with lived experience of addiction and its consequences.11,12 Each specialty will need to develop specific competencies relevant to the most common conditions and settings, with experiences and assessments to match these competencies (see Table for selected examples).Research on resident addiction medicine curricula has focused on single-site or single-specialty studies.13-15 However, a recent evaluation of the Family Medicine National Addiction Curriculum developed by the Society of Teachers in Family Medicine (STFM) found promising results, including changes in faculty and resident behaviors and practices across 25 family medicine residencies.16,17 Unique features of the STFM National Addiction Curriculum include a teacher’s guide for faculty members designed to support those with varying levels of addiction medicine expertise. Most specialty boards include only a few questions about SUD management in their certification examinations, which may provide less incentive for residency programs to include more content in the curriculum. For example, despite the high prevalence of SUD in the population18 less than 2% of the questions on the American Board of Internal Medicine certification exam concern SUDs.19 Adding SUD questions to in-training and specialty board certification examinations may further support robust development of curricular content.Another key barrier to residency SUD education is the lack of faculty expertise and faculty role models. Recognizing and providing treatment for SUDs should be a core competency for most physicians. With the US Medication Access and Training Expansion (MATE) act of 2023, the X-waiver has been replaced with a new 8-hour training requirement for the treatment of opioid and other SUDs for all Drug Enforcement Administration-registered physicians.20 While prescribing medication to treat SUDs is important, it is not sufficient. Residents should learn how to approach patients with a trauma-informed lens, motivate change, and engage patients in conversations of harm reduction. This requires faculty development and prioritization of SUD education by GME-sponsoring institutions.One option for faculty development is through continuing medical education (CME) programs such as the Provider Clinical Support System (PCSS) and the Extension for Community and Healthcare Outcomes (ECHO) programs.21 PCSS provides Buprenorphine Trainings (which have replaced the X-Waiver training) in addition to an extensive SUD 101 Curriculum. ECHO programs combine real-time virtual case discussions and didactic presentations. These programs may be used in combined faculty/resident sessions for shared learning, which can foster collegiality and mentoring opportunities. Practice-change leaders can ignite and support the pressing need for resident education and program development. National programs to support these leaders include the Boston University Clinical Addiction Research & Education Faculty Scholars Program and Chief Resident Immersion Training Program.22 The American College of Academic Addiction Medicine and American Society of Addiction Medicine provide additional CME opportunities and support for starting addiction medicine fellowships—a source for future program faculty. Many other resources are available (see online supplementary data).Currently, while many residents frequently care for patients with end-stage addiction, particularly in hospital and emergency department settings, they lack clinical experiences in optimal clinical settings.23 There is a national shortage of SUD clinical programs with experienced physician leaders.7,24,25 Thus, leaders at academic centers and teaching health systems should prioritize developing addiction medicine clinics and consult services both inpatient and...
- 1 January 2022
- Published by SAGE Publications in Substance Abuse
- Vol. 43 (1) , 1155-1162
A Qualitative Study of Patient Experiences with Telemedicine Opioid use Disorder Treatment during COVID-19
Background: The drug-related overdose crisis worsened during the COVID-19 pandemic. Recent drug policy changes to increase access to medications for opioid use disorder (MOUD) during COVID-19 shifted some outpatient MOUD treatment into virtual settings to reduce the demand for in-person care. The objective of this study was to qualitatively explore what is gained and lost in virtual patient encounters for patients with opioid use disorder at a low-threshold, addiction treatment clinic that offers buprenorphine and harm reduction services. Methods: Patients were included in this study if they received care at the Harm Reduction and BRidges to Care (HRBR) clinic and utilized virtual visits between November 2019 and March 2021. The study was conceptualized using a health care access framework and prior studies of telemedicine acceptability. Semi-structured interviews were completed between March and April 2021. Interviews were dual-coded and analyzed using directed content analysis. Results: Nineteen interviews were conducted. The sample was predominantly White (84%) and stably housed (79%) with comparable gender (male, 53%) and employment status (employed, 42%). The majority (63%) of patients preferred virtual visits compared to in-person visits (16%) or a combination of access to both (21%). Two overarching tandem domains emerged: availability-accommodation and acceptability-appropriateness. Availability-accommodation reflected participants’ desires for immediate services and reduced transportation and work or caregiving scheduling barriers, which was facilitated by virtual visits. The acceptable-appropriate domain articulated how participants felt connected to their providers, whether through in-person interactions or the mutual trust experienced during virtual visits. Conclusions: Virtual visits were perceived by participants as a valuable and critical option for accessing treatment for OUD. While many participants preferred virtual visits, some favored face-to-face visits due to relational and physical interactions with providers. Participants desired flexibility and the ability to have a choice of treatment modality depending on their needs.
- 1 January 2022
- Published by SAGE Publications in Substance Abuse
- Vol. 43 (1) , 1155-1162
A Qualitative Study of Patient Experiences with Telemedicine Opioid use Disorder Treatment during COVID-19
Background: The drug-related overdose crisis worsened during the COVID-19 pandemic. Recent drug policy changes to increase access to medications for opioid use disorder (MOUD) during COVID-19 shifted some outpatient MOUD treatment into virtual settings to reduce the demand for in-person care. The objective of this study was to qualitatively explore what is gained and lost in virtual patient encounters for patients with opioid use disorder at a low-threshold, addiction treatment clinic that offers buprenorphine and harm reduction services. Methods: Patients were included in this study if they received care at the Harm Reduction and BRidges to Care (HRBR) clinic and utilized virtual visits between November 2019 and March 2021. The study was conceptualized using a health care access framework and prior studies of telemedicine acceptability. Semi-structured interviews were completed between March and April 2021. Interviews were dual-coded and analyzed using directed content analysis. Results: Nineteen interviews were conducted. The sample was predominantly White (84%) and stably housed (79%) with comparable gender (male, 53%) and employment status (employed, 42%). The majority (63%) of patients preferred virtual visits compared to in-person visits (16%) or a combination of access to both (21%). Two overarching tandem domains emerged: availability-accommodation and acceptability-appropriateness. Availability-accommodation reflected participants’ desires for immediate services and reduced transportation and work or caregiving scheduling barriers, which was facilitated by virtual visits. The acceptable-appropriate domain articulated how participants felt connected to their providers, whether through in-person interactions or the mutual trust experienced during virtual visits. Conclusions: Virtual visits were perceived by participants as a valuable and critical option for accessing treatment for OUD. While many participants preferred virtual visits, some favored face-to-face visits due to relational and physical interactions with providers. Participants desired flexibility and the ability to have a choice of treatment modality depending on their needs.
- Open Access
- 1 August 2009
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (8) , 3337-3346
Antifungal Activity of Tamoxifen: In Vitro and In Vivo Activities and Mechanistic Characterization
Tamoxifen (TAM), an estrogen receptor antagonist used primarily to treat breast cancer, has well-recognized antifungal properties, but the activity of TAM has not been fully characterized using standardized (i.e., CLSI) in vitro susceptibility testing, nor has it been demonstrated in an in vivo model of fungal infection. In addition, its mechanism of action remains to be clearly defined at the molecular level. Here, we report that TAM displays in vitro activity (MIC, 8 to 64 μg/ml) against pathogenic yeasts (Candida albicans, otherCandidaspp., andCryptococcus neoformans). In vivo, 200 mg/kg of body weight per day TAM reduced kidney fungal burden (−1.5 log10CFU per g tissue;P= 0.008) in a murine model of disseminated candidiasis. TAM is a known inhibitor of mammalian calmodulin, and TAM-treated yeast show phenotypes consistent with decreased calmodulin function, including lysis, decreased new bud formation, disrupted actin polarization, and decreased germ tube formation. The overexpression of calmodulin suppresses TAM toxicity, hypofunctional calmodulin mutants are hypersensitive to TAM, and TAM interferes with the interaction between Myo2p and calmodulin, suggesting that TAM targets calmodulin as part of its mechanism of action. Taken together, these experiments indicate that the further study of compounds related to TAM as antifungal agents is warranted.
- 1 August 2009
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (8) , 3337-3346
Open AccessAntifungal Activity of Tamoxifen: In Vitro and In Vivo Activities and Mechanistic Characterization
Tamoxifen (TAM), an estrogen receptor antagonist used primarily to treat breast cancer, has well-recognized antifungal properties, but the activity of TAM has not been fully characterized using standardized (i.e., CLSI) in vitro susceptibility testing, nor has it been demonstrated in an in vivo model of fungal infection. In addition, its mechanism of action remains to be clearly defined at the molecular level. Here, we report that TAM displays in vitro activity (MIC, 8 to 64 μg/ml) against pathogenic yeasts (Candida albicans, otherCandidaspp., andCryptococcus neoformans). In vivo, 200 mg/kg of body weight per day TAM reduced kidney fungal burden (−1.5 log10CFU per g tissue;P= 0.008) in a murine model of disseminated candidiasis. TAM is a known inhibitor of mammalian calmodulin, and TAM-treated yeast show phenotypes consistent with decreased calmodulin function, including lysis, decreased new bud formation, disrupted actin polarization, and decreased germ tube formation. The overexpression of calmodulin suppresses TAM toxicity, hypofunctional calmodulin mutants are hypersensitive to TAM, and TAM interferes with the interaction between Myo2p and calmodulin, suggesting that TAM targets calmodulin as part of its mechanism of action. Taken together, these experiments indicate that the further study of compounds related to TAM as antifungal agents is warranted.